Protocol Set for Amivantamab Acneiform Rash

Researchers establish a new management plan to mitigate skin side effects in patients receiving combination cancer therapy.

Updated on Oct. 27, 2026 in Asthma

Gouache-painted illustration of a glass dropper on a white surface, representing clinical precision in managing dermatological side effects for cancer patients. — Researchers have introduced the COCOON protocol to manage acneiform rashes that frequently occur during amivantamab and lazertinib combination therapy for cancer patients. AI Illustration. Upload story photo >

Live Poll

Do you believe minimizing treatment side effects should be prioritized over maintaining continuous medication dosages?

Wade Iams has introduced the COCOON prophylaxis protocol to manage acneiform rashes that frequently occur in patients treated with amivantamab and lazertinib. The regimen is designed to address skin reactions emerging on the face and chest during the initial phase of cancer care.

Why it matters

Managing dermatological side effects is crucial for maintaining patient adherence to potent cancer treatment regimens. This protocol provides a structured approach to minimizing discomfort while ensuring patients can continue their therapeutic course.

The COCOON prophylaxis regimen mandates the use of doxycycline twice daily, supplemented by chlorhexidine nail soaks and regular moisturizing. Clinicians utilize topical clindamycin to treat facial or scalp rashes, with dose modifications contingent on severity.

The players

Wade Iams

Wade Iams is a clinical researcher who developed the COCOON protocol to manage side effects for patients undergoing specific cancer therapies.

Tennessee Oncology

Tennessee Oncology is a specialized medical institution serving as a clinical site for the development and testing of cancer management protocols.

Starling Oncology

Starling Oncology is a clinical facility that provided expert input during the development of the dermatological management strategies.

The details

The management strategy relies on the COCOON regimen to preemptively address skin issues, with clinicians verifying patient adherence to the routine. When rashes manifest, medical teams utilize topical clindamycin and adjust therapy dosages based on the level of patient disruption.

Acneiform rashes typically develop on the face and chest at week 3 of treatment.

The Big Picture

This protocol marks a move toward systematic dermatological support within the COCOON prophylaxis regimen framework. It formalizes a standard for addressing treatment-related toxicities that have historically challenged patients on targeted oncology therapies.

Patients undergoing this cancer treatment should maintain strict adherence to the prescribed daily moisturizing and medication schedule to reduce the likelihood of severe rashes. Clear communication with clinicians regarding skin sensitivity at the three-week mark allows for timely dosage adjustments.

The takeaway

Proactive management of skin reactions can significantly improve the quality of life for individuals receiving complex cancer treatments. Patients should monitor their skin closely during the first month of therapy and report any discomfort to their care team immediately.